Company Enlivex Therapeutics Ltd. Deutsche Boerse AG

Equities

1BT

IL0011319527

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Tradegate Other stock markets 12:39:11 2024-04-25 pm EDT			5-day change	1st Jan Change
1.385 ^EUR	+13.52%		+0.73%	-40.00%

Apr. 22	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
Apr. 16	Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	MT

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Managers	Title	Age	Since
Oren Hershkovitz CEO	Chief Executive Officer	47	19-11-15
Dror Mevorach FOU	Founder	68	08-12-31
Shachar Shlosberger DFI	Director of Finance/CFO	47	15-12-31
Veronique Amor-Baroukh COO	Chief Operating Officer	-	-
Sigal Arad HRO	Human Resources Officer	-	-
Iris Tavor LAW	General Counsel	-	-
Einat Galamidi PRN	Corporate Officer/Principal	-	22-02-21
Oren Elmaliah AUD	Comptroller/Controller/Auditor	40	17-01-31

Members of the board	Title	Age	Since
Shai Novik CHM	Chairman	58	19-03-25
Avri Havron BRD	Director/Board Member	75	13-12-31
Brian Schwartz BRD	Director/Board Member	52	20-11-30
Roger Pomerantz BRD	Director/Board Member	67	22-05-22
Gili Hart BRD	Director/Board Member	49	13-12-31
Andrew Singer BRD	Director/Board Member	53	23-04-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,598,555	14,984,878 ( 80.57 %)	0	80.57 %

Name	Equities	%	Valuation
Kip Global Pharma Ecosystem Private Equity Fund 7.628 %	1,417,950	7.628 %	5 M €
Hadasit Bio-Holdings Ltd. /Private Equity/ 5.412 %	1,006,007	5.412 %	4 M €
Shai Novik 4.055 %	753,764	4.055 %	3 M €
Dror Mevorach 1.262 %	234,657	1.262 %	889 350 €
Avri Havron 0.9568 %	177,852	0.9568 %	674 059 €
Renaissance Technologies LLC 0.3340 %	62,089	0.3340 %	235 317 €
KSM Mutual Funds Ltd. 0.2686 %	49,925	0.2686 %	189 216 €
Morgan Stanley Capital Services LLC 0.2392 %	44,460	0.2392 %	168 503 €
IBI Mutual Funds Management (1978) Ltd. 0.2246 %	41,750	0.2246 %	158 233 €
Susquehanna Securities LLC 0.1502 %	27,925	0.1502 %	105 836 €

Enlivex Therapeutics Ltd.

14 Einstein Street

7403618, Ness Ziona

http://www.enlivex.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.5 USD

Average target price

7 USD

Spread / Average Target

+366.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.20%	104B
REGENERON PHARMACEUTICALS, INC.	+1.49%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-18.06%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-16.16%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.14%	13.98B
SAREPTA THERAPEUTICS, INC.	+34.74%	11.66B

Bio Therapeutic Drugs